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Abstract
Background: Lower respiratory tract infection is a common cause of consultation and antibiotic prescription in
paediatric practice. The misuse of antibiotics is a major cause of the emergence of multidrug-resistant bacteria.
The aim of this study was to evaluate the frequency, changes over time, and determinants of non-compliance
with antibiotic prescription recommendations for children admitted in paediatric emergency department (PED)
with community-acquired pneumonia (CAP).
Methods: We conducted a prospective two-period study using data from the French pneumonia network that
included all children with CAP, aged one month to 15 years old, admitted to one of the ten participating paediatric
emergency departments. In the first period, data from children included in all ten centres were analysed. In the
second period, we analysed children in three centers for which we collected additional data. Two experts assessed
compliance with the current French recommendations. Independent determinants of non-compliance were
evaluated using a logistic regression model. The frequency of non-compliance was compared between the two
periods for the same centres in univariate analysis, after adjustment for confounding factors.
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Results: A total of 3034 children were included during the first period (from May 2009 to May 2011) and 293 in the
second period (from January to July 2012). Median ages were 3.0 years [1.4–5] in the first period and 3.6 years in
the second period. The main reasons for non-compliance were the improper use of broad-spectrum antibiotics or
combinations of antibiotics. Factors that were independently associated with non-compliance with recommendations
were younger age, presence of risk factors for pneumococcal infection, and hospitalization. We also observed
significant differences in compliance between the treatment centres during the first period. The frequency of
non-compliance significantly decreased from 48 to 18.8 % between 2009 and 2012. The association between period
and non-compliance remained statistically significant after adjustment for confounding factors. Amoxicillin was
prescribed as the sole therapy significantly more frequently in the second period (71 % vs. 54.2 %, p < 0.001).
Conclusions: We observed a significant increase in the compliance with recommendations, with a reduction in the
prescription of broad-spectrum antibiotics, efforts to improve antibiotic prescriptions must continue.
Keywords: Pneumonia, Antibiotic prescription, Antibiotic stewardship, Children
Background
In paediatrics, pneumonia frequently leads to medical
consultations, antibiotic prescriptions, and hospitalization
[1, 2]. In 2005, the French health authorities published
guidelines for prescribing antibiotics, especially for
community-acquired pneumonia (CAP) [3]. In these
recommendations, amoxicillin is the first-line treatment
recommended for suspected pneumococcal infections.
Treatment with macrolides is recommended only in cases
of subacute clinical presentation in older children.
However, merely publishing recommendations is not a
guarantee for compliance with them [4, 5]. Moreover,
it has been shown that antibiotic resistance is closely
linked to inadequate and improper antibiotic intake,
highlighting the need for better ways to control antibiotic
usage [6].
With growing concern about the widespread problems
associated with antibiotic resistance, improved steward-
ship of paediatric antibiotics usage is being promoted in
France through a national network (GPIP: Groupe de
Pathologie Infectieuse Pédiatrique), in which most
members have a particular interest in emergency care. In
a study published 2012, Angoulvant et al. evaluated the
impact of the antibiotic guidelines for acute respiratory-
tract infection on antibiotic prescribing practice in a
paediatric emergency department. They found a signifi-
cant decrease of the antibiotic prescriptions from 32 to
21 % (p < 0.001, Cochran-Armitage test) [7]. Limiting
the use of antibiotics is an effective way to reduce selec-
tion pressure, but when an antibiotic is indicated, in the
case of pneumonia, for example, it is also important to
prescribe the antibiotic appropriately with the optimal
dosage and the narrowest spectrum that is likely to be
effective. Indeed, guidelines for the management of
upper respiratory tract infections, published in 2011,
recommended a narrowing of the spectrum of antibi-
otics used. We hypothesized that these guidelines could
have had an impact on the antibiotic prescription for
CAP [8].
The aim of this study was to evaluate the extent and
temporal course of non-compliance with current anti-
biotic prescription recommendations for paediatric CAP
in paediatric emergency department (PED). We exam-
ined clinical practice in ten French PED, five years after
the guidelines were published. The secondary objec-
tives were to describe the cause of any medical non-
compliance with these recommendations and to study




We conducted a prospective two-period study using data
from the French pneumonia network that included all
children with CAP, aged one month to 15 years old, who
presented at one of the ten participating PED [9]. CAP
was assessed based on the association of a fever with
consolidation on a chest X-ray [10]. All children admit-
ted in PED, whether to be subsequently discharged
home or hospitalized, were eligible for inclusion. The
detailed methodology of this network is detailed else-
where [9]. During the first period (from 1 May 2009 to 1
May 2011), we analysed the antibiotic prescriptions for
children admitted to the ten PED. To evaluate the ad-
equacy of the antibiotic prescriptions more accurately
and add further detail to our initial results, we collected
additional data during a second period (from 1 January
2012 to 1 July 2012) from three of the participating
centres. These data concerned the patients’ character-
istics and clinical features, as well as details about
any antibiotic prescription. Exclusion criteria included
the presence of empyema or the absence of data ne-
cessary to evaluate compliance with the prescribing
guidelines.
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The Robert Debré Hospital Ethics Committee approved
the French pneumonia network, with informed consent
waived.
Collected data
Prospectively collected data available from the national
network were demographic characteristics (age, sex);
data about past medical history, particularly the presence
of risk factors for pneumococcal disease (among them
immune deficit, asplenia, sickle cell disease, chronic lung
disease); clinical data (fever level, respiratory symptoms,
presence of severity signs, such as respiratory distress or
appearing ill); radiological data; microbiological data
(blood culture); data concerning antibiotics prescribed in
the PED (name and administration route); and data
concerning outcome (hospitalization, apyrexia at 48 h
follow-up and surviving status). Patients were followed
for 48 h if seen as outpatients or followed until discharge
if hospitalized. Deaths that occurred either in PED or
during subsequent hospitalization were reported.
In period 2, some supplemental data were prospect-
ively collected concerning clinical features helping to
discriminate pneumococcal (sudden onset) from intra-
cellular bacteria (subacute onset, myalgia or rash). More
precise data about the antibiotic drug prescribed in the
PED (dosage and duration), as well as data concerning
the justification of the choice of antibiotic drug and its
administration route (previous prescription of antibiotic
for the same episode, allergy to antibiotic, vomiting,
haemodynamic failure, or altered consciousness), were
also collected. For feasibility reasons, these supplementary
data were collected from only three chosen centres that
comprised the largest proportion of study participants
eligible for inclusion (representing 43 % of all inclusions in
period 1).
Assessment of compliance
Compliance with the prescription recommendations was
assessed by 2 paediatric emergency physicians collect-
ively (KL and FL). If there was any uncertainty, a third
expert specializing in paediatric infectious diseases was
asked to decide (CGL).
Compliance was evaluated according to the algorithm
recommended by the health authorities (Fig. 1). Anti-
biotic prescription was considered as non-compliant
according to these recommendations if: (i) a macrolide
was prescribed as the first choice treatment in children
younger than 3 years of age or in children with acute
disease or septic signs, whatever their age; (ii) oral ceph-
alosporin, cotrimoxazole, tetracycline, or azithromycin
were prescribed as first line therapy; (iii) amoxicillin/
clavulanate was prescribed in the absence of associated
otitis or in children well-vaccinated against Haemophilus
infuenzae serotype b; (iv) a combination of antibiotics
(amoxicillin plus macrolide) was prescribed as a first line
treatment in the absence of respiratory distress requiring
intensive care; (v) an antibiotic was administered intra-
venously in the absence of known allergy to penicillin
(which would justify the use of IV cephalosporin), and in
the absence of severe respiratory distress, haemodynamic
Fig. 1 Algorithm of antibiotic choice recommended by the French health authorities in 2005
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failure, altered consciousness, or vomiting; or (vi) if
the dosage was insufficient compared to that recom-
mended by health authorities (80–100 mg/kg/day for
amoxicillin) [3].
To evaluate the non-compliance in period 1, the asses-
sors used the following information: age, clinical features
(respiratory distress, ill appearance, temperature), nature
and administration route of the antibiotic drug pre-
scribed. In period 2, the same information as in period 1
was used, as well information concerning (i) the onset of
the disease (sudden—suggestive of Pneumococcus; or pro-
gressive—suggestive of atypical bacteria), (ii) the presence
of vomiting, altered consciousness or haemodynamic fail-
ure justifying the use of IV antibiotic administration, (iii)
the presence of allergy (justifying the use of a drug other
than amoxicillin), (iv) the presence of extra-pulmonary
symptoms (suggesting atypical bacteria), (v) the presence
of associated otitis, (vi) the status for anti-Haemophilus b
vaccine and (vii) the dosage of the antibiotic drug pre-
scribed. Due to the lack of information concerning anti-
biotic drug dosage in period 1, this was not evaluated for
compliance in period 1. In addition, as there was a lack of
data concerning allergy in period 1, the IV administration
of a third-generation cephalosporin was considered as
non-compliant if administered in outpatients. Moreover,
the use of amoxicillin–clavulanate was considered as non-
compliant in period 1, as data on associated otitis or
vaccination status for Haemophilus were lacking.
The development of the non-compliance between the
two periods was assessed by comparing the frequency of
non-compliant prescribing at the three centres included
in both periods of the study.
Statistical analysis
For the univariate analyses (comparing the compliant to
non-compliant group or period 1 to period 2), we used
either the chi-squared or Fisher’s exact test to compare
the tabulated variables and either Student’s t-test or the
Mann–Whitney U-test to compare the continuous vari-
ables. The potential determinants of non-compliance
were age, signs of severe illness (defined as an ill appear-
ance or respiratory distress), presence of risk factors for
pneumococcal infection, hospitalization, centre, and quali-
fication of the prescribers (for period 2 only). Independent
factors associated with non-compliance with prescription
recommendations were studied using multivariate analysis
in the form of a logistic regression, selecting only those
variables for which p < 0.1 in the univariate analysis. For
period 1, we tested a hierarchical regression model that
took into account the hierarchical structure of the data at
a centre level (i.e., patients within a centre are not
independent), which enabled us to construct a model for a
‘centre effect’. The hierarchical model could not be used
in period 2 due to the small number of participating
centres [11]. We compared the frequency of non-
compliance for the three centres included in the two pe-
riods of the study with a chi-squared test for the univariate
analysis. We adjusted the comparison of confounding fac-
tors (those previously identified as determinants of non-
compliance) using logistic regression. As the duration and
the seasons of collecting data were different (24 months in
period 1 and 6 months in period 2), we tested the varia-
bility of non-compliance with seasons thanks to a chi-
squared test (seasons were defined as winter from January
to March, spring from April to June, summer from July to
September and fall from October to December). We also
included season as a potential confounder in the multi-
variate analysis. Quantitative variables were tested for
linearity, transformed into polynomials, and categorized if
they deviated. For analysis, we used Stata, v11 (StataCorp;





During the first period, 3354 patients were seen in the
PED network (including the 10 centres). We excluded
270 children with empyema and 50 missing data crucial
to being evaluated for compliance with the recommen-
dations. Amongst the remaining 3034 children, the me-
dian age was 3.0 years old and 32.2 % were hospitalized.
Six children died (Table 1). Amoxicillin was prescribed
in 58.1 % of the cases (Table 2).
Second period
During the second period, 300 patients were included
from three participating centres (centres 2, 3, and 7).
We excluded six children with empyema and one child
for whom data about their antibiotic prescription(s) were
missing. Among the 293 children that were included, the
median age was 3.6 years old and 26.7 % were hospital-
ized. Two children died (Table 1). Amoxicillin was pre-
scribed in 71.0 % of the cases (Table 2). The antibiotics
were prescribed for 10 days for 73.4 % of the children,
with a median prescribed duration of 10 days (ranging
from 2 to 15 days).
Compliance with recommendations
First period
Non-compliance with the current recommendations for
antibiotic prescriptions occurred in 48.5 % of the cases
included in the 10 centres. The most frequent reasons
for non-compliance, in order of frequency, were as fol-
lows: the use of an antibiotic that was too broad-spectrum
for the disease (amoxicillin-clavulanate or third generation
cephalosporin) in 69.8 % of the non-compliant cases;
unjustified intravenous (IV) administration in 37.2 %;
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Table 1 Demographics and clinical features of the children according to their compliance with recommendations and period of the study (numbers are percentages with
denominators mentioned at the top of the column, except for those with superscript letters) with univariate and multivariate analyses for factors associated with prescription
non-compliance (by period)













Univariate analysis Multivariate analysis
OR 95 % CI p aOR 95 % CI p OR 95 % CI p aOR 95 % CI p








16.6 8.3 24.4 3.7 3–4.7 <0.001 3 2.4–3.9 <0.001 14 14.7 10.7 1 - -
Age >1 year
(%)




28.5 20.5 36.5 2.3 1.9–2.7 <0.001 1 0.8–1.3 0.71 26.7 27.4 23.6 0.8 0.4–1.6 0.56
Ill appearance
(%)




5.7 3.5 8.1 2.4 1.8–3.5 <0.001 1.4 0.95–2.1 0.09 6.8 3.4 21.4 7.8 2.9–21.1 <0.001 4.1 1.3–12.7 0.02
Centres (%)
Centre 1 5.4 53.6 46.4 1 - - 1 - -
Centre 2 12.4 60.6 39.4 0.8 0.5–1.1 0.13 0.9 0.5–1.3 0.37 34 85 15 1 - - 1 - -
Centre 3 20.5 48.8 51.2 1.2 0.9–1.7 0.27 1.2 0.8–1.8 0.48 32 87 13 2.4 1.2–4.9 0.01 1.3 0.6–3.1 0.53
Centre 4 13.1 36.6 63.4 2 1.4–2.9 <0.001 2 1.3–3 0.002
Centre 5 4.8 22,1 77.9 4.1 2.4–6.9 <0.001 1.7 0.9–3.1 0.06
Centre 6 12.3 65.5 34.5 0.6 0.4–0.9 0.009 0.6 0.4–0.9 0.02
Centre 7 9.6 47.8 52.2 1.3 0.9–1.9 0.23 0.9 0.6–1.5 0.79 34 70 30 0.8 0.4–1.9 0.68 0.6 0.2–1.5 0.19
Centre 8 0.6 47.1 52.2 1.3 0.5–3.5 0.61 0.7 0.2–2.5 0.61
Centre 9 17.8 63.5 36.5 0.7 0.5–0.9 0.02 0.7 0.5–1.1 0.17
Centre 10 3.4 25.2 74.8 3.4 2–6 <0.001 1.9 1–3.6 0.05
Season
Winter 25.3 25.3 25.2 1 - - 1 78.5 76.4 87.5 1 - 1 - -
Spring 17 18.4 15.6 0.7 0.6–0.9 0.01 0.7 0.5–0.9 0.012 21.5 23.6 12.5 0.5 0.2–1.1 0.07 0.5 0.2–1.4 0.18
Summer 15 15.4 14.7 0.8 0.7–1.6 0.15 0.8 0.6–1.1 0.25 - - - - - -











Table 1 Demographics and clinical features of the children according to their compliance with recommendations and period of the study (numbers are percentages with
denominators mentioned at the top of the column, except for those with superscript letters) with univariate and multivariate analyses for factors associated with prescription





74.2 76.2 73.5 0.9 0.6–1.1 0.26 68.9 72.9 61.1 0.6 0.2–1.4 0.21
CRP
≥40 mg/L
53.9 55.6 53.8 0.9 0.7–1.1 0.18 55.2 55.8 54.1 0.9 0.4–2.1 0.86
PCT ≥2
mg/mL




3.6 3.2 3.8 1.2 0.5–2.8 0.71 4.9 2.9 7.7 3.2 0.3–39.6 0.33
Prescriber (%)
Resident 53.4 44.4 55.5 1 - - 1 - -
Fellow 21.2 22.3 16.7 0.9 0.4–2.2 0.87 0.6 0.2–1.5 0.29
Senior 25.4 22.3 38.9 2.2 1.4–4.3 0.02 1.7 0.8–3.5 0.19
Hospitalization
(%)
32.2 12.4 51.9 7.6 6.2–9.2 <0.001 5.7 4.6–7.2 <0.001 26.7 22 46.3 3.1 1.6–5.7 <0.001 4.1 2–8.4 <0.001




89.8 90 89.6 0.9 0.7–1.3 0.77 81.7 83.1 78.1 0.7 0.3–2 0.53
Death 0.2 0.2 0.2 1 0.2–5.3 0.9 0.7 0.8 0
Table 1 legend: OR odds ratio, aOR adjusted odds ratio, 95%CI 95 % confidence interval, IQR interquartile range, PICU Paediatric Intensive Care Unit
*age was non-linear in period 1 and was transformed to a second degree polynomial as follows: x1 = ln(X) − 0.3 and x2 = X
0,5 − 1.2 (where: X = age/1000) in the univariate analysis, age was entered as a dichotomous
variable (around 1 year) in the multivariate analysis
**age was normally distributed in period 2 and was entered as a continuous variable in the multivariate analysis
arisk factors for pneumococcal infection were reported for 2992 children during period 1
bin period 1, white blood cell counts (WBC) were done for 1228 children, C-reactive protein (CRP) for 1394, procalcitonin (PCT) for 396, and blood cultures for 838 children; in period 2, WBC was done for 106 children,
CRP for 114, and PCT for 44











Table 2 Description of the antibiotic prescriptions in the two periods of the study. n(%)
Period 1 (10 centres) Period 1 (3 centres) Period 2 (3 centres) p*
Total Compliant Non-compliant Total Compliant Non-compliant Total Compliant Non-compliant
N = 3034 N = 1562 N = 1472 N = 1292 N = 672 N = 620 N = 293 N = 237 N = 56
Mode
None 126 (4.1) 0 126 (8.6) 9 (0.7) 0 9 (1.5) 1 (0.3) 0 1 (1.8) 0.5
Oral 2292 (75.5) 1558 (99.7) 734 (49.8) 1035 (80.6) 669 (99.7) 366 (59.0) 257 (87.7) 221 (92.9) 36 (27.3) 0.002
IV 616 (20.3) 4 (0.3) 612 (41.6) 248 (19.4) 3 (0.3) 245 (39.5) 35 (12) 16 (7.1) 19 (70.9) 0.003
Generic name
Amoxicillin 1764 (58.1) 1526 (97.7) 238 (17.6) 700 (54.2) 655 (97.5) 45 (7.3) 208 (71) 203 (87.1) 5 (4.1) <0.001
Amoxicillin +macrolide 98 (3.2) 3 (0.3) 95 (7.1) 49 (3.8) 1 (0.2) 48 (7.7) 13 (4.4) 0 13 (20.4) 0.6
3rd G cephalosporin 277 (9.1) 1 (0.1) 276 (19.5) 157 (12.2) 0 157 (25.3) 15 (5.1) 6 (2.6) 9 (18.3) <0.001
Macrolide 93 (3.1) (1.6) 68 (4.9) 46 (3.6) 10 (1.5) 36 (5.8) 16 (5.5) 11 (4.7) 5 (10.2) 0.13
Pristinamycin 6 (0.2) 5 (0.2) 1 (0.1) 5 (0.4) 4 (0.6) 1 (0.2) 2 (0.7) 0 2 (4.1) 0.5
C3G +Macrolide 17 (0.6) 0 17 (1.2) 13 (1) 0 13 (2.1) 0 0 0 0.09
Azithromycin 28 (1) 0 28 (2.1) 0 0 0 5 (1.7) 0 5 (10.2) <0.001
Amoxicillin-Clavulanate 574 (18.9) 0 574 (40.1) 278 (21.5) 0 278 (44.8) 22 (7.5) 12 (5.2) 10 (16.3) <0.001
Others 51 (1.7) 4 (0.3) 47 (7.4) 35 (2.71) 2 (0.3) 33 (5.3) 11 (3.8) 0 11 (16.4) 0.4











unjustified concomitant administration of two or more
antibiotics in 13.2 %; prescription of a macrolide despite
amoxicillin being the preferred treatment in 4.8 %; and no
antibiotics prescribed in 8.6 %. Among 126 children who
did not receive antibiotics, 68 were described as ill-
appearing or having respiratory distress signs and/or
having risk factors for pneumococcal infection.
Second period
Non-compliance with the current recommendations for
antibiotic prescriptions was seen in 18.8 % of the cases.
The most frequent reasons for non-compliance, in order
of frequency, were as follows: the use of unjustified
concomitant administration of two or more antibiotics
in 38.2 % of non-compliant cases; treatment that was
too broad-spectrum for the disease (amoxicillin-clavula-
nate or third generation cephalosporin) in 36.4 %;
prescription of a macrolide or pristinamycin despite
amoxicillin being the preferred treatment in 9.1 %; the use
of a macrolide not approved by the French medical agency
for CAP indications in 9.1 %; unjustified IV administration
in 3.6 % and insufficient dosage in 3.6 %;
Determinants of non-compliance with recommendations
First period
In the univariate analysis, factors associated with non-
compliance were as follows: an age of less than one year;
signs that the disease was severe; the presence of risk
factors for pneumococcal infection; centre of admission;
and need for hospitalization. The antibiotic prescriptions
were less often non-compliant during the spring season
compared to winter season. In the multivariate analysis,
independent factors significantly associated with non-
compliance with prescriptions were as follows: an age of
less than one year; being hospitalized; and admission
into PED centre 4 or 10. Using a hierarchical regression
model, the associations between non-compliance and
age, and between non-compliance and hospitalization,
were unchanged (the adjusted odds ratio [aOR] and
95 % confidence interval [CI 95 %] did not vary; see
Additional file 1: Table S1). We did not find any differ-
ence in outcomes (apyrexia occurring at 48 h or death)
between the compliant and non-compliant groups.
Second period
In the univariate analysis, factors associated with non-
compliance were as follows: age (as a continuous variable);
the presence of risk factors for pneumococcal infection;
centre of admission; qualifications of the prescriber
(seniority); and the need for hospitalization. Compliance
did not significantly varied with season during the period
2 but there was a trend for less non-compliant prescrip-
tion during spring as observed in period 1. In the
multivariate analysis, independent factors significantly
associated with non-compliance with prescriptions were:
age (with a linear association); risk factors for pneumococ-
cal infection; and hospitalization (Table 1). We did not
find any differences between non-compliant and compli-
ant groups and their association with the occurrence of
apyrexia at 48 h.
Comparison of the two periods
The three centres (2, 3 and 7 in Table 1) included in
period 2 represented 1292 of the 3034 patients that were
seen during period 1. If we consider only those three
centres, non-compliance decreased from 48 % in period
1 to 18.8 % in period 2 (p < 0.001). Amoxicillin was
prescribed as the sole therapy significantly more fre-
quently in period 2 at these three centres (71 % vs.
54.2 %, p < 0.001) (Table 2). After adjustment for con-
founding factors, period 2 remained statistically associ-
ated with a lower risk of non-compliance (aOR = 0.2;
95 % CI: 0.1-0.3; p < 0.001) (Table 3). Considering only the 2
Table 3 Factors independently associated with non-compliance
(results of the logistic regression). This analysis included only
those children seen in the three centres participating in period
2 of the study
Compliant Non compliant aOR CI 95 % p
N = 909 N = 676
n (%) n (%)
Period
First period 672 (52.0) 620 (48.0) 1 - -
Second period 237 (80.9) 56 (18.5) 0.2 0.1–0.3 <0.001
Age
< 1 year 97 (33.8) 190 (62.6) 1 - -
> 1 year 812 (66.2) 486 (37.4) 0.4 0.3–0.5 <0.001
Risk factors for pneumococcal infection
No 859 (59.2) 591 (40.8) 1 - -
Yes 30 (21.3) 66 (68.7) 2.4 1.4–4.1 0.002
Respiratory distress
No 687 (64.0) 386 (36.0) 1 - -
Yes 207 (43.0) 275 (57.0) 0.8 0.6–1.1 0.62
Ill appearance
No 679 (63.3) 394 (36.7) 1 - -
Yes 208 (44.4) 260 (55.6) 1.3 0.9–1.7 0.11
Season
Winter 353 (38.8) 233 (34.5) 1 - -
Spring 173 (19) 106 (15.7) 0.8 0.6–1.1 0.21
Summer 105 (11.6) 95 (14) 1 0.7–1.5 0.97
Fall 278 (30.6) 242 (35.8) 0.9 0.6–1.2 0.44
Hospitalization
No 783 (70.7) 324 (29.3) 1
Yes 117 (25.2) 348 (74.8) 7 5.1–9.7 <0.001
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seasons (winter and spring) that were both studied
during the 2 periods of the study, the period 2 remained in-
dependently associated with a lower risk of non-compliance
with the same aOR (see Additional file 2: Table S2).
Discussion
In this prospective observational study, we found that
non-compliance with recommendations for antibiotic pre-
scriptions in paediatric CAP was frequent in paediatric
emergency department, but decreased from the first to
the second period (48 % vs. 18.8 %), with a greater use of
amoxicillin as monotherapy at Period 2. Although compli-
ance improved during this period, the main reasons for
non-compliance were still the improper use of broad-
spectrum antibiotics or combinations of antibiotics.
Factors those were independently associated with the
non-compliance with recommendations included younger
age (less than 1 year old), presence of risk factors for
pneumococcal infection, and hospitalization. Further-
more, we observed significant differences in compliance
between the treatment centres during period 1.
The increase in amoxicillin use during the period of
study could partly be the result of the Hawthorne effect,
meaning that clinicians may have improved their com-
pliance with the recommendations because they knew
that they were being evaluated on this point. However,
the GPIP network was not set up primarily to evaluate
prescriptions, and the prescribers in each centre were
not aware of the objectives of this ancillary study. The
high proportion of non-compliance with prescriptions
that occurred during period 1 could be partially due to a
classification bias. Indeed, accurate information concern-
ing the patients’ particularities (such as allergies, pres-
ence of comorbidities, etc.) was collected during the
second period but not during the first period. Although
these data could have justified the use of broad-
spectrum antibiotics, this type of antibiotic was pre-
scribed to a lesser extent during period 2. For example,
the use of amoxicillin–clavulanate was considered as
non-compliant in period 1, because information about
associated otitis or vaccination status against Haemophi-
lus influenzae was not available; in contrast, in period 2,
such information was available and therefore could be
taken into account, thus justifying the prescription of
amoxicillin–clavulanate. However, amoxicillin–clavula-
nate was significantly less prescribed in period 2. This
indicates that the prescriptions were more often judged
as compliant, due to an actual improvement in adhering
to the guidelines, rather than a change in the way
compliance was evaluated during the two periods of the
study. The increase in amoxicillin use observed in our
study between periods 1 and 2 is consistent with the
findings reported in a study by Smith et al., which
showed that, after the implementation of guidelines
recommending the use of amoxicillin, prescription
rates of amoxicillin for CAP increased from 2 to
44 % [12].
We observed that younger ages were associated with a
higher risk of non-compliance in period 1, whereas, by
contrast, the aOR for non-compliance was 1.2 for each
year of age in period 2. This could be attributed to the
increased likelihood that during the first period, young chil-
dren were more likely to receive amoxicillin-clavulanate
than in the second period. The use of amoxicillin-
clavulanate could be explained by the fear of invasive
Haemophilus influenzae type b. We also observed that
children with risk factors for invasive pneumococcal infec-
tion were more likely to be subject to non-compliant pre-
scriptions, particularly during period 2. We hypothesize
that doctors might fear, in an irrational manner, encoun-
tering resistant pneumococci in these children. Indeed,
since the more widespread use of the pneumococcal vac-
cine, resistance to penicillin has decreased, as described in
a previous Palestinian–Israeli study [13]. This decrease in
the resistance to penicillin was also observed in France,
with 82 % of the 1858 strains analysed by the national
reference centre being susceptible to amoxicillin in 2009
vs. 92 % of the 957 analysed strains in 2012 (p < 0.001)
[14, 15]. The use of broad spectrum antibiotics was
therefore needed less often. It has also been shown that
antibiotic guidelines for upper respiratory tract infec-
tions, published on November 2011 in France, had a
major impact on antibiotic prescriptions, resulting in
increased amoxicillin use [14]. These recommenda-
tions could have also impacted the antibiotic prescrip-
tions for pneumonia in our study by sensitizing
prescribers to the need to use narrow-spectrum anti-
biotics in order to limit the risk of resistant bacteria.
The absence of antibiotic prescription was considered
as non-compliant. It could be argued that children who
did not receive antibiotics were suspected of having a
viral infection, which therefore obviated the need for
antibiotics. French health authorities recommended, in
2005, to perform a chest X-ray in cases where CAP is
suspected and to treat all cases of CAP with antibiotics,
as the differentiation between viral and bacterial infec-
tions is not easy to distinguish [3]. The latest guideline
from the British Thoracic Society also recommends
for all children with pneumonia to be treated with
antibiotics; however, the Society also stated that fully
vaccinated children of less than 2 years old of age
with mild lower respiratory symptoms are not likely
to have bacterial pneumonia (but rather viral pneu-
monia) and therefore require no chest X-rays or anti-
biotics [16]. The American recommendations from the
Pediatric Infectious Diseases Society and the Infectious
Diseases Society of America also stated that ‘Antimicrobial
therapy is not routinely required for preschool-aged
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children with CAP, because viral pathogens are respon-
sible for the great majority of clinical disease’ (strong
recommendation; high-quality evidence) [17]. There-
fore, challenging the diagnosis of bacterial pneumonia
in fully vaccinated children younger than 2 years old
with mild symptoms is another way to reduce anti-
biotic use.
Assessors did not take into account the prescribed
duration of antibiotics in their evaluation of compliance,
as the information was not available during period 1.
The French recommendations are to treat for 10 days if
a pneumococcal infection is suspected, whereas the
American guidelines recommend the shorter effective
treatment. A systematic review, published in 2008, found
evidence that a short course of 3 days was as effective as
a longer course of 5 days of antibiotics for children
younger than 5 years old with non-severe CAP in devel-
oped countries. However, these results could not be gen-
eralized, as the inclusion criteria were not restricted to
bacterial pneumonia [18]. Therefore, the shorter effect-
ive treatment still remains to be defined in developed
countries.
This study has several limitations. Firstly, the evalu-
ation of compliance was not done independently by sev-
eral experts; however, the existence of precise guidelines
made the evaluation less subjective. Secondly, some data
were missing, but this was only an issue for 50 children
in period 1 (1.6 %) and one in period 2 (0.3 %). Thirdly,
the 10 centres from period 1 (particularly those with the
highest aOR) were not all included in period 2, risking
undervaluation for non-compliance during period 2.
Nevertheless, the mean non-compliance from period 1
was very similar in these three centres to the mean of all
ten: 48.0 % compared with 48.5 %. Finally the 2 periods
of the study differed in their length with 4 seasons cov-
ered in period 1 and only 2 seasons in period 2. This
could have limited the relevance of the comparison be-
tween the 2 periods. To avoid this potential risk of bias
we adjusted the comparison between the two periods on
the seasons and we also made a comparison restricted to
the 2 seasons that were both studied in the 2 periods. In
the 2 cases, we found a significant decrease of non-
compliance in period 2 with an aOR at 0.2 (95 % CI
0.1–0.3).
Conclusion
A reduction in the prescription of broad-spectrum anti-
biotics is feasible by reducing the use of broad-spectrum
drugs that are no longer justified in the treatment of
‘typical’ CAP, since the incidence of penicillin-resistant
Pneumococcus is decreasing [13], by avoiding overtreat-
ment of viral pneumonia with antibiotics [17, 18] and by
reducing the treatment duration to a shorter effective
course [19].
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